معرفی
Richard Bucala, MD, PhD, is the Waldemar Von Zedtwitz Endowed Professor of Medicine, Pathology, and Epidemiology at Yale School of Medicine. He serves as Chief of the Section of Rheumatology, Allergy & Immunology and holds affiliations with the Yale Institute for Global Health and multiple interdisciplinary centers. His research focuses on immune system regulation, particularly the role of macrophage migration inhibitory factor (MIF) in autoimmune diseases, infections, and cancer. He pioneered the molecular cloning of MIF and discovered its critical role in glucocorticoid resistance, leading to therapies like Imalumab and Milatuzumab. His work extends to global health, including genetic epidemiology studies in malaria and tuberculosis, and the discovery of fibrocytes in fibrosing disorders. Dr. Bucala co-founded MIFCOR and has served on UN, federal, and industry advisory boards.
Education: MD and PhD from Cornell and Rockefeller University, with postdoctoral training at Harvard and Institut Pasteur.
Research interests span MIF biology, genetic susceptibility to disease, and translational immunotherapies. Key contributions include allele-specific MIF therapies, fibrocyte targeting in fibrosis, and structure-based drug design for autoimmune/infectious diseases. His lab also investigates MIF-like proteins in parasites, offering vaccine development insights.
Publications highlight MIF's role in cancer, atherosclerosis, and immune responses, with recent focus on allele-selective inhibitors and MIF/DDT signaling networks. He leads NIH-funded projects and collaborates widely in oncology, rheumatology, and global health.
